April 16, 2025

Can ctDNA Monitoring Help to Predict Melanoma Recurrence?

A new report shows how droplet digital polymerase chain reaction assays focusing on monitoring the most common mutations in the genetic code in melanoma cells—BRAF V600E and BRAF V600K—may help to pre...

The ASCO Post

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post

September 19, 2023

Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab

In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues investigated the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodru...

The ASCO Post

January 05, 2024

Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer

Researchers investigated the potential of a rare subset of T cells to predict which patients with advanced skin cancer may be responsive to immunotherapy.

The ASCO Post

February 19, 2024

FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma

On February 16, the FDA granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for previously treated adult patients with unresectable or metastatic mel...

The ASCO Post

August 12, 2024

Pattern in Protein Production May Be Predictive of Side Effects From Immunotherapy in Patients With Melanoma

An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases may predict the occurrence of severe side effects from immunotherapy in patients with melanoma.

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

August 21, 2023

Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests

Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent s...

The ASCO Post

May 22, 2024

Use of the 31-Gene Expression Profile Test to Aid in the Decision of Adjuvant Treatment of Cutaneous Melanoma

A 61-year-old man diagnosed with nodular malignant melanoma underwent gene expression profiling to guide treatment decisions and remains recurrence-free at 53 months post-diagnosis.

JADPRO